Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Factor bb as a biomarker during breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria

View Full Paper
Ask AI
Bookmark
Share

Authors

DPDaniel C. PayneMGMorag GriffinAPAlexandra Pike

Discussion

Loading...

Member takes

Overview

Observational study found elevated biomarker levels during breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria, indicating complement activation.

Key Points

  • The research investigates the role of Factor Bb as a biomarker during breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria.
  • Blood samples collected from 66 patients with PNH during clinic visits and during 17 breakthrough hemolysis events.
  • Patients categorized based on complement inhibitor treatment.
  • FBb levels measured using Quidel MicroVue Bb Plus Fragment EIA.
  • FBb levels positively correlated with lactate dehydrogenase and negatively with hemoglobin.
  • FBb significantly elevated during breakthrough hemolysis (mean 5.5ug/ml).
  • FBb levels in untreated patients higher than those on treatment without BTH.

Cite This Study

Payne et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df7ehttps://doi.org/10.1182/blood-2025-4973
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The effect of breakthrough hemolysis on complement factor h and factor I levels in paroxysmal nocturnal hemoglobinuria2025
  2. 2Real-world data on breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with proximal and terminal complement inhibitors.2025
  3. 3Characterization of Breakthrough Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria: An International Multicenter Experience.2025 · 6 citations
  4. 4Real-world breakthrough hemolysis patterns across 1,723 patient-years of complement inhibition in paroxysmal nocturnal hemoglobinuria2025
  5. 5The role of red blood cell lifespan in evaluating the condition of patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors2025